JAK1/JAK3 inhibitor — same class effect as baricitinib. Approved for RA, psoriatic arthritis, ulcerative colitis. ORAL Surveillance trial showed worse CV + malignancy signal vs TNFi → boxed warning.
Half-Life & Elimination Curve (PO: 3h)
Plasma (PO)t½ Decay (3h)Effect Site (ke0)
0×t½0h100%(57.6 µg/L)
1×t½3h50%(28.8 µg/L)
2×t½6h25%(14.4 µg/L)
3×t½9h12.5%(7.2 µg/L)
4×t½12h6.3%(3.6 µg/L)
5×t½15h3.1%(1.8 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.54h
Est. Peak (Cmax)57.6 µg/L
Clearance (CL)20.8 L/h
97% Washout (5×t½)15h
Dosing Guidelines
Oral (PO): Typical 10 mg (Range: 5–22 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 74% · Volume of Distribution (Vd): 90 L · Absorption (ka): 1.4 h⁻¹ (t½ka ≈ 30m) [PMID 33062629]